Exhibit Booth Demonstrations and Participation in Expert Master Course Highlight BrainsWay’s Expanding Role in Psychiatric CareBURLINGTON, Mass. and JERUSALEM, May 01, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, is proud to announce its participation at the American Psychiatric Association (APA) Annual Meeting, taking place May 17–21, 2025, in Los Angeles, California. As part of the meeting’s ...

| Date: | Tuesday, May 13, 2025 | | --- | --- | | Time: | 8:30 AM Eastern Time | | United States: | 1-877-300-8521 | | International: | 1-412-317-6026 | | Israel: | 1-80-921-2373 | | Conference ID: | 10198731 | | Webcast: | Link | BURLINGTON, Mass. and JERUSALEM, April 29, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it will report its first q ...

Core Insights - Inspire Medical Systems, Inc. is a medical technology company specializing in minimally invasive solutions for obstructive sleep apnea [3] - The company will present at the BofA Securities 2025 Health Care Conference on May 13, 2025, at 2:20 p.m. Eastern Time [2] - Inspire's proprietary therapy is the first and only FDA, EU MDR, and PDMA-approved neurostimulation technology for treating moderate to severe obstructive sleep apnea [3] Company Information - Inspire focuses on the development and commercialization of innovative solutions for obstructive sleep apnea [3] - The company’s Inspire therapy is recognized for its safety and effectiveness in treating the condition [3] - Additional information about Inspire can be found on their official website [3]

Company Overview - Nexalin Technology, Inc. is focused on developing innovative neurostimulation products aimed at addressing the global mental health epidemic, utilizing non-invasive bioelectronic medical technology [4] - The company's neurostimulation devices are designed to penetrate deep brain structures associated with mental health disorders, potentially enhancing patient response without adverse side effects [4] Upcoming Event - Nexalin will host a webinar on April 3, 2025, at 4:15 p.m. ET, featuring CEO Mark White, who will discuss the company's clinical data and advancements in its Gen-3 HALO™ Clarity & Virtual Clinic model [2][3] - The webinar will include a live Q&A session, allowing investors to engage directly with the CEO [2] Market Potential - Nexalin's solutions have demonstrated clinically meaningful improvements in treating conditions such as insomnia, PTSD, and traumatic brain injuries, which affect millions and have limited effective treatments [2] - The mental health market is projected to reach $537 billion by 2030, indicating substantial growth potential for Nexalin's products [2]